The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary ...

Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026; Lorigerlimab Phase 2 LINNET study update in mid-2026; IN ...

Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

A landmark Oxford-led analysis of 1.8 million people has found that non-meat diets significantly slash the risk of several cancers, including a 31% drop in multiple myeloma.